The BMJ’s regional advisory board will give this important region a louder voice
In recent decades, Latin America has made important contributions to global health. Although substantial economic and social inequalities and political instability continue to adversely affect population health, the region is developing knowledge, health policies, and experience that deserve wider recognition. Contributions include Latin America’s efforts in social medicine, especially in social security and nutrition1; national public policies that have become a world reference, such as the compulsory licensing of an AIDS drug in Brazil in 20072; and the health cooperation agenda intended to create a platform for solidarity focusing on infrastructure, health, security, and natural resources within the framework of the now dissolved Union of South American Nations.3
Building on these contributions, and to help boost the region’s profile and leadership in global health, The BMJ has established its f
Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb ViiV Healthcare, the global specialist HIV company majority owned
Although the COVID-19 vaccines are safe to administer to patients who no longer have symptoms, randomized studies have not evaluated the best time to vaccinate patients who have recovered.
The era of exclusive triple therapy for the treatment of HIV may be coming to an end as evidence mounts in support of the safety and efficacy of new dual-therapy (two-drug) regimens. The era of exclusive triple therapy for the treatment of HIV may be coming to an end as evidence mounts in suppo.